Tango Therapeutics, Inc. $TNGX Shares Sold by Trv Gp Iv LLC

Trv Gp Iv LLC cut its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 17.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,863,975 shares of the company’s stock after selling 2,995,100 shares during the quarter. Tango Therapeutics makes up approximately 42.5% of Trv Gp Iv LLC’s investment portfolio, making the stock its 2nd largest holding. Trv Gp Iv LLC owned approximately 10.30% of Tango Therapeutics worth $116,457,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TNGX. Dynamic Technology Lab Private Ltd grew its stake in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after acquiring an additional 15,037 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Tango Therapeutics by 78.8% in the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock valued at $40,000 after buying an additional 3,452 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Tango Therapeutics by 44.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after buying an additional 2,907 shares during the period. Finally, Northeast Financial Consultants Inc acquired a new stake in Tango Therapeutics during the second quarter worth approximately $51,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Activity

In related news, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the completion of the sale, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at $2,259,481.22. The trade was a 5.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Adam Crystal sold 54,345 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $12.77, for a total value of $693,985.65. Following the completion of the transaction, the insider owned 132,873 shares in the company, valued at approximately $1,696,788.21. This represents a 29.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 133,884 shares of company stock worth $1,724,622. Company insiders own 7.50% of the company’s stock.

Tango Therapeutics Stock Up 0.9%

Shares of TNGX stock opened at $17.30 on Friday. Tango Therapeutics, Inc. has a twelve month low of $1.03 and a twelve month high of $17.63. The stock’s fifty day simple moving average is $12.67 and its 200 day simple moving average is $9.79. The firm has a market capitalization of $2.47 billion, a P/E ratio of -19.88 and a beta of 1.76.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. As a group, equities research analysts expect that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TNGX. Guggenheim lifted their price objective on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 6th. Stifel Nicolaus boosted their price target on Tango Therapeutics from $15.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Jefferies Financial Group reiterated a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a research note on Thursday, March 5th. Wedbush boosted their target price on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Finally, Wall Street Zen lowered shares of Tango Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.50.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.